Navigation Links
Alexza and Grupo Ferrer Amend Adasuve™ Partnership
Date:3/7/2012

liance with Grupo Ferrer," said Thomas B. King, Alexza's President and CEO.  "In the first four months of our partnership, teams from both companies have worked to expand the integration of the ADASUVE work, strategies and responsibilities.  We share great passion for the product and a strong sense of camaraderie toward building long-term success."

King continued, "We are also excited to support Ferrer's upcoming submissions of the ADASUVE registrations for Brazil and Mexico.  We feel these filings demonstrate Ferrer's commitment to ADASUVE as they work to bring this important product to patients."

About ADASUVE (Staccato loxapine)
ADASUVE is an anti-agitation therapeutic that combines Alexza's proprietary Staccato system with loxapine, an antipsychotic drug.  Loxapine is currently available in oral and other formulations, inside and outside of the U.S. and European Union.  The Staccato system is a hand-held, single-dose inhaler that delivers a drug aerosol to the deep lung that results in IV-like pharmacokinetics and rapid systemic effects.  Click here to see an animation of how the Staccato system works.

As an easy-to-use, non-coercive and highly reliable inhaled therapeutic that has been shown to produce a rapid reduction in agitation, Alexza believes that ADASUVE meets the three key attributes for the treatment of acute agitation as specified in the American Association of Emergency Psychiatrists' Expert Consensus Guidelines for the Treatment of Behavioral Emergencies: speed of onset, reliability of medication delivery and patient preference.  Similarly, the National Institute for Health and Clinical Excellence (commonly referred to as "NICE") Clinical Practice Guidelines describe an ideal treatment for agitation as having a low level of side effects and a rapid onset of action, and that i
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Announces Proposed Public Offering of Common Stock and Warrants
2. FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexzas ADASUVE™
3. Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference
4. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
5. Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
6. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
7. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
8. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
9. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
10. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5sqnn3/global_rising ) ... Stars Outlook 2015" report to their offering. ... sought after with fresh vigor as new targets , ... poised to bring a paradigm change in the way ... Stem cell therapy/Regenerative Medicine space. The number ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. ... multi-disciplinary clinical specialty, aimed at improving patient care ... individually adjust the dose of drugs for improving ...
(Date:3/5/2015)... March 5, 2015  MGC Diagnostics Corporation (NASDAQ: ... company, today reported financial results for the first ... 2015 first quarter domestic equipment, supplies and accessories ... $3.7 million in the 2014 first quarter.  During ... or $338,000 in revenue, compared to 14 accounts, ...
Breaking Medicine Technology:Global Pharma Rising Stars Outlook 2015 2Global Therapeutic Drug Monitoring Report 2015 - Technologies, Markets, and Companies Analysis 2014-2024 2MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 2MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 3MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 4MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 5MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 6MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 7MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 8MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 9MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 10MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 11MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 12
... (Nasdaq: ATHX ), a clinical stage ... Retail Investor Conferences.com presentation is available for on-demand ... Executive Officer of Athersys, presented to retail investors ... To view the archived presentation, click on ...
... Corporation, a privately held, clinical stage biopharmaceutical company developing ... today announced the appointment of Dr. Dennis Fenton, long-time ... Fenton,s appointment expands the Genelux Corporation board to 5 ... build one of the world,s most successful pharmaceutical companies ...
Cached Medicine Technology:Athersys, Inc. - Retail Investor Conferences.com Presentation Now Available Online 2Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive 2
(Date:3/5/2015)... 05, 2015 Supply & Demand Chain ... of “Pros to Know” in the supply chain industry, ... of MEBC’s leadership team were included on this year’s ... received this award due to their hard work, their ... for meeting and resolving client needs and challenges. ...
(Date:3/5/2015)... New York, NY (PRWEB) March 05, 2015 ... NY orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named ... in the New York Metro area. Dr. Glashow has ... in its authoritative guide to the top specialty care ... 2015. , The prestigious Castle Connolly program, which carefully ...
(Date:3/5/2015)... March 05, 2015 As a ... (AAPA) review of Clearstream, LLC ’s products, ... Clearstream’s MediDefense line of products—led by their mPulse ... Affinity Partner Program. , The AAPA—which represents a ... all medical and surgical specialties in the U.S.—advocates ...
(Date:3/5/2015)... Diego, CA (PRWEB) March 05, 2015 ... it is now running on 100% pollution-free electricity ... Arcadia Power. , As an Arcadia Power ... Protection Agency’s (EPA) Green Power Partnership requirements, joining ... Starbucks that also purchase clean energy. Earth Source ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... 2007) -- A University of South Florida fetal surgeon ... rare but potentially devastating condition in which placental blood ... labor, leaving the baby without vital blood and oxygen. ... frequently deadly for newborns. , The case was ...
... delaying surgical treatment remains the standard of care for ... in the December issue of the Journal of the ... belief, early cholecystectomy -- or surgical removal of the ... mild to moderate gallstone pancreatitis with no increase in ...
... Inc. (Nasdaq:,CYBX) announced that effective December 18, 2007, ... Endo-Surgery granting exclusive rights to,the company,s patents and ... the treatment of obesity and two related,co-morbidities, diabetes ... has agreed to pay Cyberonics a signing fee ...
... 18 DuPont has selected,its Cooper River plant ... announced to significantly expand production of high-performance,DuPont(TM) Kevlar(R) ... The investment at the Cooper River site, which ... Berkeley County, will include construction of,a new Kevlar(R) ...
... WALTHAM, Mass., Dec. 18 Art Mellor is one ... million worldwide suffering from,Multiple Sclerosis (MS). It,s, a debilitating ... other,symptoms. So it,s no wonder that Mellor, the founder ... interested in snow and more,interested in raising the funds ...
... 17, 2007) -- The Leon Levy Foundation has ... Hospital/Weill Cornell Medical Center in New York City ... neurological disorders: chemotherapy-related cognitive dysfunction in adult cancer ... as "water on the brain," a progressive neurologic ...
Cached Medicine News:Health News:Fetal surgeon shows for first time that laser procedure may treat vasa previa 2Health News:Fetal surgeon shows for first time that laser procedure may treat vasa previa 3Health News:Early surgical treatment contributes to better outcomes in gallstone pancreatitis cases 2Health News:Cyberonics Licenses Obesity-Related Patents 2Health News:Cyberonics Licenses Obesity-Related Patents 3Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 2Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 3Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 4Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 5Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 3Health News:$1.4 million grant awarded to study 2 little-understood neurological disorders 2
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
The Diamedix immunosimplicity® Is- Rheumatoid Factor Test Kit is an EIA procedure intended for the quantitation of IgM antibodies to IgG antigen. The results are reported in IU/mL, traceable to t...
RFScan Latex Test Kit-100...
Medicine Products: